Organon & Co. (OGN)
| Market Cap | 3.79B |
| Revenue (ttm) | 6.41B |
| Net Income (ttm) | 1.30B |
| Shares Out | 257.54M |
| EPS (ttm) | 5.04 |
| PE Ratio | 2.92 |
| Forward PE | 3.77 |
| Dividend | $1.12 (7.60%) |
| Ex-Dividend Date | Nov 12, 2024 |
| Volume | 2,308,031 |
| Open | 14.59 |
| Previous Close | 14.59 |
| Day's Range | 14.46 - 14.77 |
| 52-Week Range | 10.84 - 23.10 |
| Beta | 0.80 |
| Analysts | Hold |
| Price Target | 21.33 (+44.81%) |
| Earnings Date | Oct 31, 2024 |
About OGN
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple o... [Read more]
Financial Performance
In 2023, Organon & Co.'s revenue was $6.26 billion, an increase of 1.44% compared to the previous year's $6.17 billion. Earnings were $1.02 billion, an increase of 11.56%.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for OGN stock is "Hold." The 12-month stock price forecast is $21.33, which is an increase of 44.81% from the latest price.
News
Organon: 7% Yield, 4x P/E, Big Upside Potential
Organon is a deep value stock with a high 7.2% yield, supported by a diversified portfolio in women's health, biosimilars, and established pharmaceuticals. Despite stock price volatility, OGN has show...
Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)
In this update, I'll focus on Organon's Q3 2024 results, earnings adjustments and segment performance, as well as the acquisition of Dermavant. Organon reported solid Q3 2024 results with 4% revenue g...
Organon & Co. (OGN) Q3 2024 Earnings Call Transcript
Organon & Co. (NYSE:OGN) Q3 2024 Earnings Call Transcript October 31, 2024 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Juan Camilo Arjona Ferreira - Head of R&D Matt Wal...
Organon Reports Results for the Third Quarter Ended September 30, 2024
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon Reports Q3 2024 Earnings.
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon expands dermatology capabilities through completion of Dermavant acquisition, including nonbiologic, non-steroidal VTAMA Cream, 1%.
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
5 Stocks to Buy for a Harris Presidency
The race for the White House is heating up and these five stocks are set to benefit if Kamala Harris claims victory.
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a focus on women's health, will release its third quarter 2024 financial results on October 31, 2024, prior to...
Final Trades: Organon, Howmet and the PSQ
The Investment Committee give you their top stocks to watch for the second half.
Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B
Organon & Co OGN has agreed to acquire Roivant Sciences Ltd's ROIV Dermavant Sciences Ltd, which is focused on developing and commercializing therapeutics in immunodermatology.
Roivant Flips a Skin Drug to Organon
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, and then selling them for big returns.
Organon to buy therapy developer Dermavant for up to $1.2 billion
Healthcare company Organon said on Wednesday it has agreed to acquire Dermavant, a Roivant company, for up to $1.2 billion.
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters agreement to acquire Dermavant including innovative VTAMA (tapinarof) cream, 1%, a novel, non-steroidal topical dermatologic therapy.
JP Morgan Shows Most Interest In Teva, Organon As Specialty Pharma Sector Exhibits Signs Of Stability
JP Morgan notes that while there's a resurgence of interest and excitement in new product launches within the specialty group, including branded and complex generics/biosimilars, investors should be d...
Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon & Lilly expand migraine commercialization agreement to 11 more markets.
Organon & Co. (OGN) Q2 2024 Earnings Call Transcript
Organon & Co. (NYSE:OGN) Q2 2024 Earnings Call Transcript August 6, 2024 8:30 AM ET Company Participants Jennifer Halchak - Head of IR Kevin Ali - CEO Matt Walsh - CFO Conference Call Participants Um...
Organon Reports Results for the Second Quarter Ended June 30, 2024
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon reports results for Q2 2024, ended June 30, 2024.
Top 4 stocks that could thrive if Kamala Harris wins the 2024 US election
As the 2024 US presidential election approaches, speculation about Kamala Harris potentially stepping into the Oval Office remains strong. Despite Donald Trump's assertion that Harris would be an eas...
Organon: Upcoming Q2 Earnings Can Sustain Upward Momentum
Organon stock experienced significant downside pressure in 2023, however positive Q423 and Q124 earnings have led to a bull run. Organon's business includes women's health, biosimilars, and establishe...
20 value stocks with high dividend yields and expected room to raise payouts
Last week's action in the stock market might have signaled a long-awaited shift away from a focus on Big Tech in the stock market to overlooked pockets of value.
Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon will report Q2 2024 results and host conference call on August 6, 2024. Organon estimates $15M milestone expenses in second quarter.
CUPE 37 Members Reject City of Calgary Wage Package
CALGARY, Alberta--(BUSINESS WIRE)--Matt Sjogren, President of CUPE 37 (City of Calgary outside workers) issued the following statement after employees rejected a contract settlement offer. Last night,...
European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
SHANGHAI, China & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $OGN #denosumabbiosimilar--European Medicines Agency validates Organon and Henlius marketing authorization filings for Prolia and Xgeva (denosu...
Organon Graduates From Spinoff Skepticism, With A Yield Above 5%
Organon, Pfizer, and Bristol Myers all offer yields above 5% and can compete with most Treasuries, but only Organon is up YTD. Spinoffs often struggle in their initial years, but Organon's partial re...